Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group by Veal, G J et al.
Pharmacokinetics and metabolism of 13-cis-retinoic acid
(isotretinoin) in children with high-risk neuroblastoma – a study of
the United Kingdom Children’s Cancer Study Group
GJ Veal
1, M Cole
1, J Errington
1, ADJ Pearson
2, ABM Foot
3, G Whyman
4 and AV Boddy*,1on behalf of the
UKCCSG Pharmacology Working Group
1Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK;
2Royal Marsden Hospital, Surrey SM2
5PT, UK;
3Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK;
4UKCCSG, University of Leicester, Leicester LE1 6TH, UK
The administration of 13-cis-retinoic acid (13-cisRA), following myeloablative therapy improves 3-year event-free survival rates in
children with high-risk neuroblastoma. This study aimed to determine the degree of inter-patient pharmacokinetic variation and
extent of metabolism in children treated with 13-cisRA. 13-cis-retinoic acid (80mgm
 2 b.d.) was administered orally and plasma
concentrations of parent drug and metabolites determined on days 1 and 14 of courses 2, 4 and 6 of treatment. Twenty-eight
children were studied. The pharmacokinetics of 13-cisRA were best described by a modified one-compartment, zero-order
absorption model combined with lag time. Mean population pharmacokinetic parameters included an apparent clearance of
15.9lh
 1, apparent volume of distribution of 85l and absorption lag time of 40min with a large inter-individual variability associated
with all parameters (coefficients of variation greater than 50%). Day 1 peak 13-cisRA levels and exposure (AUC) were correlated
with method of administration (Po0.02), with 2.44- and 1.95-fold higher parameter values respectively, when 13-cisRA capsules
were swallowed as opposed to being opened and the contents mixed with food before administration. Extensive accumulation of
4-oxo-13-cisRA occurred during each course of treatment with plasma concentrations (mean7s.d. 4.6773.17mM) higher than those
of 13-cisRA (2.8371.44mM) in 16 out of 23 patients on day 14 of course 2. Extensive metabolism to 4-oxo-13-cisRA may influence
pharmacological activity of 13-cisRA.
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The retinol derivative 13-cis-retinoic acid (13-cisRA) is now an
established component of the treatment of high-risk neuroblasto-
ma, despite the fact that early phase II trials conducted with
low-dose 13-cisRA showed limited clinical benefit in patients with
recurrent disease (Reynolds et al, 1991; Finklestein et al, 1992;
Kohler et al, 2000). When 13-cisRA was administered as a high-
dose (160mgm
 2day
 1), intermittent regimen in a Children’s
Cancer Group phase III randomised trial, a significant improve-
ment in 3-year event-free survival (EFS) was observed (Matthay
et al, 1999). Factors that may explain the efficacy observed in the
latter study include the higher dose administered and the use of an
intermittent dosing regimen, incorporating 2-weeks of 13-cisRA
followed by a 2 week rest period, on each course of treatment
(Matthay and Reynolds, 2000).
Retinoids are susceptible to oxidative metabolism, and the
extensive metabolism of all-trans-retinoic acid (ATRA) in acute
promyelocytic leukaemia (APL) may influence relapse rates
(Muindi et al, 1992). Analysis of patient samples from a phase I
study of 13-cisRA previously suggested increasing levels of the
metabolite 4-oxo-13-cisRA during a course of treatment, although
actual concentrations were not quantified (Khan et al, 1996).
An additional concern with the administration of 13-cisRA is
that many neuroblastoma patients are very young. Owing to the
large size and number of 13-cisRA capsules required to obtain the
specified dose, younger children are physically unable to take the
drug unless the capsules are opened and the contents mixed with
food before administration. This practice raises concerns regard-
ing the actual dose of drug that these patients are receiving, in
addition to the possibility that the drug may be unstable during
this procedure.
The current study was designed to determine the pharmaco-
kinetics of 13-cisRA and the extent of oxidative metabolism when
administered to high-risk neuroblastoma patients using an
intermittent dosing regimen. In addition, the absorption of 13-
cisRA when administered following opening of the capsules and
mixing the contents with food was investigated.
MATERIALS AND METHODS
Patient eligibility and treatment
The study protocol was approved by the UK Trent Multicentre
Research Ethics Committee and written informed consent was
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sobtained from patients or parents as appropriate. Patients less
than 18 years with a central venous catheter, who were receiving
13-cisRA as part of their standard clinical treatment, were eligible.
13-cis-retinoic acid (80mgm
 2b.d.) was administered orally as
part of a protocol for high-risk neuroblastoma (Matthay et al,
1999), starting between 80 and 120 days post-myeloablative and
radiation therapy in all cases. Drug was administered for 14 days,
with a 14 day break before the next course. Toxicity was assessed
by the National Cancer Institute Common Toxicity Criteria (CTC
version 2.0) and patients were followed clinically on a 6-monthly
basis. In patients who were unable to swallow the capsules, each
capsule was snipped with a pair of scissors and the contents
extruded into ice-cream or yoghourt before ingestion. Patients
were not fasted before administration. On each day of the study,
the administration of the studied dose of 13-cisRA was performed
in hospital, supervised by a trained research nurse and fully
documented.
Patient details
Age and weight together with 13-cisRA administration details were
recorded for each patient. Glomerular filtration rate (GFR) was
estimated according to the equation:
GFR (ml/min)¼36.76þ1.91*weight (kg) 0.47*serum creati-
nine (mmoll
 1) (Cole et al, 2004).
The most recent ALT, bilirubin and creatinine measurements
before 13-cisRA treatment were obtained from the patients’ notes
(mean 26 days before administration, maximum 63 days prior).
Blood sampling and analysis
Blood samples for measurement of concentrations of individual
retinoids were obtained from a central line before administration
and at 1, 2, 4 and 6h post-administration. Samples were obtained
on days 1 and 14 (first and last day) of treatment courses 2, 4 and 6
following administration of the first dose of 13-cisRA on the
particular study day. When sampling on these courses was not
possible, samples were obtained on days 1 and 14 of an alternative
treatment course. Course 1 was not studied in most cases to allow
the families and patients to become familiar with the administra-
tion processes. Blood samples (5ml) were collected in heparinised
tubes and centrifuged at 1200g for 10min at 41C. Plasma was
separated and frozen at  201C, before analysis using a high-
performance liquid chromatography assay, with a limit of
quantitation of 0.02mgml
 1 for all retinoids. This analytical assay
allowed for individual quantification of 13-cisRA, 9-cisRA and
ATRA, in addition to the metabolite 4-oxo-13-cisRA, as previously
described (Veal et al, 2002). All blood and plasma samples were
wrapped in aluminium foil to protect them from light, and all
sample handling was carried out in dim light. The assay was
validated with regard to linearity, reproducibility and stability of
the analytes according to standard practice (Shah et al, 1992).
Pharmacokinetics/statistical analysis
A population pharmacokinetic analysis was carried out using 13-
cisRA plasma concentrations obtained on study day 1 from the
first available course of treatment for each of 28 patients (course 1
for five patients, course 2 for 20 patients and courses 3, 4 and 6 for
one patient each). Peak and trough 13-cisRA levels from days 1 and
14 were determined, together with peak levels of the metabolite
4-oxo-13-cisRA on day 1 and 14; these were compared between
treatment courses 2, 4 and 6.
Using NONMEM (Beal and Sheiner), a series of population
pharmacokinetic models were fitted to 13-cisRA data from the first
available course of treatment, with all patients included in the
analysis. A one-compartment model with first-order absorption
(ADVAN2) was fitted using the FOCE estimation method with Z, e
interaction. A composite within-subject error model was used
together with an exponential between-subject error model for each
of the population PK parameters (CL, V, Ka). Models were fitted
using firstly, a diagonal, and then a full block structure for the
between-subject covariance matrix. An absorption time lag was
added, which was also allowed to vary across the population. A
zero order absorption model with an absorption lag was also fitted
(ADVAN1); both the absorption lag time and absorption duration
were allowed to vary across the population.
Two further models were fitted to try to more closely model the
absorption phase. The first was a ‘transit model’, which assumes
that the absorption delay is due to the passage of drug through
a chain of transit compartments (Savic et al, 2004). The number
of transit compartments and the rate at which the drug moves
between each of the compartments were estimated from the data.
The model was parameterised in terms of CL, V, Ka, N (the number
of transit compartments) and the MTT (the mean transit time to
the absorption compartment). The second model was a modified
zero-order absorption model with an absorption lag time. This
model assumes that the appearance of the drug in a dose
compartment is described by a zero-order process over a fixed
duration (D). Absorption into a central compartment was
described by a first-order process with rate parameter Ka. This
model was parameterised in terms of CL, V, Ka, LAG and D. Both
of these models allowed all pharmacokinetic parameters to vary
between individuals according to an exponential error model; both
were fitted using ADVAN2.
The relationships between pharmacokinetic parameters (appar-
ent clearance, AUC and apparent volume of distribution), peak
concentrations of 13-cisRA and 4-oxo-13-cisRA on days 1 and 14 of
treatment, and covariates were examined graphically and either
t-tests or linear regression applied as appropriate. The pharma-
cokinetic parameter estimates used were the empirical Bayes
estimates obtained from the modified zero-order absorption
model, except the peak concentrations. Covariates investigated
were age, weight, ALT, bilirubin, creatinine, GFR, sex, method of
administration and CTC grade 3/4 toxicity. The logarithm of all
pharmacokinetic parameters and continuous covariates was used
in preference to the untransformed variables owing to the skewed
nature of the data. Empirical Bayes estimates of pharmacokinetic
parameters for courses 4 and 6, where data were available, were
obtained from the final population model.
The Cox proportional hazards model was used to investigate
any relationship between pharmacokinetic end points, including
peak levels of 13-cisRA and 4-oxo-13-cisRA on days 1 and 14 on
the first available course of treatment, and time to relapse/
progression of disease, relative to the first 13-cisRA
administration.
RESULTS
Patient characteristics and treatment
Twenty-nine children were entered into the study. One patient had
to withdraw from the study before samples being taken, owing to
removal of their central venous catheter. The study population had
a median age of 3.2 years (range 1.1–18.7) and included 16 male
and 12 female patients. Patient characteristics for the 28 evaluable
patients are given in Table 1.
Pharmacokinetics
The pharmacokinetics of 13-cisRA were best described by a
modified one-compartment, zero-order absorption model com-
bined with an absorption lag time (LAG) allowing a full covariance
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smatrix for the random effects. The differential equations for the
final model are:
dX1ðtÞ
dt
¼
0
X0
D   kaX1ðtÞ
 kaX1ðtÞ
8
<
:
if toLAG
if LAGptoD þ LAG
if tDþ LAG
dX2ðtÞ
dt
¼ ka:X1ðtÞ 
CL
V
:X2ðtÞ;
where X0 is the dose of 13cisRA administered at time t¼0 and
assumed to enter the system at time t¼LAG; X1(t) is the amount
of drug in the dose compartment at time t; X2(t) is the amount of
drug in the observation compartment at time t; D is the duration of
the zero-order input; ka is the rate of the first-order absorption; CL
is apparent clearance and V is apparent volume of distribution.
However, both the transit model and the first-order absorption
model with lag time gave very similar parameter estimates and
individual fits, despite having slightly larger objective function
values (Table 2). Mean population pharmacokinetic parameters
were; apparent clearance 15.9lh
 1, apparent volume of distribu-
tion 85l and absorption lag time 40min. There was large inter-
individual variability associated with these parameters. Clearance
had an inter-individual CV of 69%, while both volume of
distribution and Ka had CVs in excess of 100%. Correction of
clearance or volume of distribution for body surface area did not
reduce the CV (Table 3).
There was a large degree of variation between courses in day 1
13-cisRA levels (Figure 1; Tables 3 and 4). Whereas some patients
showed little variation between courses (e.g. patients 15 and 20),
others exhibited large differences (e.g. patients 2 and 7). In
contrast, variation in 13-cisRA levels between study days (1 and
14) of the same course, in particular course 2, was relatively small
(Figure 2A).
Owing to difficulties in obtaining stable parameter estimates, the
inclusion of covariates into a population pharmacokinetic model
was not undertaken. Instead, the relationship between pharmaco-
kinetic parameter estimates and covariates was examined via plots
and either t-tests or linear regression as appropriate. 13-cis-
retinoic acid AUC and day 14 peak 4-oxo-13-cisRA levels were
both found to be related to weight, age and whether or not the
capsule had been opened before administration. Higher weight
and age were also associated with larger AUCs and peak 4-oxo-
13-cisRA levels (Po0.02 in all cases). Day 1 peak 13-cisRA
concentrations were found to be linked to method of administra-
tion (Po0.02). When 13-cisRA capsules were swallowed, AUC was
found to be on average 1.95-fold larger (95% confidence interval
(CI) 1.16, 3.28) than when capsules were opened; day 1 peak 13-
cisRA levels were 2.44-fold higher (CI 1.23, 4.83) and day 14 peak
4-oxo-13-cisRA levels were 2.65-fold higher (CI 1.41, 5.00) when
capsules were unopened. Figure 3 shows AUC values for 13-cisRA
Table 1 Patient characteristics
Characteristic No. of patients %
Age (years)
o38 2 9
3–5 13 46
6–10 4 14
11–18 3 11
Sex
Male 16 57
Female 12 43
Weight (kg)
o10 1 3
10–20 21 75
20–30 3 11
430 3 11
Disease stage
3 (with MYCN amplification) 2 7
4 (age 41year) 26 93
MYCN amplification
Yes 15 54
No 13 46
Table 2 Comparison of population pharmacokinetic parameter estimates for various models; coefficient of variation (%) shown in paranthesis
Model OFV CL/F Ka V/F LAG/MTT NN D
Zero-order absorption with lag time 50.1 10.53 (89.4) — 111.1 (100.0) 27.39 (44.7) — 57.40 (70.7)
First-order absorption with lag time 24.3 15.40 (63.8) 0.050 (236) 64.07 (102) 53.52 (11.7) — —
Modified zero-order absorption with lag time 13.8 15.87 (68.6) 0.068 (154) 84.77 (92.1) 40.04 (27.2) — 11.8 (200.0)
Transit model 18.5 15.55 (63.9) 0.054 (207) 72.24 (93.5) 57.40 (52.2) 20.09 (36.2) —
OFV, objective function value; CL/F, apparent clearance (lh
 1); Ka, absorption rate (1min
 1); V/F, apparent volume of distribution (l); LAG, absorption lag time (min); MTT, mean
time to absorption transition (min); NN, number of transit compartments; D, absorption duration (min).
Table 3 Summary statistics for empirical Bayes pharmacokinetic
parameter estimates on study day 1, analysed by course
Parameter Course N Mean s.d. Min Median Max
CL/F (lh
 1) 2 26 20.7 16.7 4.8 17.8 80.8
4 12 12.5 6.7 3.4 11.1 24.7
6 10 13.2 6.9 7.1 10.9 30.7
V/F (l) 2 26 121.1 128.7 21.6 75.0 490.2
4 12 40.9 22.1 13.2 38.2 100.3
6 10 68.8 57.2 30.1 41.4 194.4
AUC (mmolhl
 1) 2 26 13.2 9.0 2.1 10.5 37.3
4 12 20.8 11.0 6.1 20.2 43.7
6 10 17.2 8.1 5.4 15.8 31.3
CL/F (lh
 1m
 2) 2 26 31.9 27.2 7.7 24.0 136.2
4 12 17.7 11.4 5.9 13.4 41.0
6 10 19.1 12.4 7.6 15.8 51.2
V/F (lm
 2) 2 26 177.4 173.7 29.7 125.7 662.7
4 12 58.8 39.7 21.7 51.3 168.3
6 10 100.5 94.9 34.0 55.6 324.5
LAG (min) 2 26 41.2 10.6 23.7 39.0 57.7
4 12 49.4 7.8 37.8 52.5 62.5
6 10 43.7 7.5 31.9 44.1 54.5
CL/F, apparent clearance; LAG, absorption lag time; AUC, area under the curve,
extrapolated to infinity; N, number of patients studied on each course of treatment.
CL/F and V/F also given as values corrected for body surface area. Course 2 refers to
first available course. This was course 1 in 5 patients and course 3 in one patient.
13-cis-retinoic acid pharmacokinetics in children
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sobserved on day 1 of course 2 of treatment in patients who
swallowed 13-cisRA capsules vs patients for whom the capsule
contents were mixed with food.
Larger absolute doses of 13-cisRA were associated with higher
day 14 peak 4-oxo-13-cisRA levels (P¼0.01). A larger 13-cisRA
apparent volume of distribution was associated with higher
creatinine levels (P¼0.02), but none of the covariates were found
to be related to apparent clearance of 13-cisRA, peak 13-cisRA
levels from day 14 or peak 4-oxo-13-cisRA levels from day 1.
Oxidative metabolism
Extensive accumulation of 4-oxo-13-cisRA occurred in all patients
during each treatment course, with plasma concentrations higher
than those of 13-cisRA on day 14 of course 2 of treatment in 16 out
of 23 patients for whom data were available (Figure 4; Table 4).
In course 2, peak concentrations of 4-oxo-13-cisRA increased
from 0.2 to 5.9mM on day 1 to 0.7–11.6mM on day 14 of treatment,
as compared with 13-cisRA plasma concentrations of 0.3–5.5mM
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Figure 1 13-cis-retinoic acid data; study day 1 for all patients shown by course; separate graphs shown by method of administration. Patient 26 received
13cisRA via an NG tube.
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son day 14. Similar increases in the level of metabolite over the 14
days of treatment were observed in subsequent courses (Figure 4).
No other retinoic acid metabolites were detected in plasma
samples of patients receiving 13-cisRA and concentrations of
ATRA accounted for less than 5% of total retinoids in all samples.
Clinical response and toxicity
Of the 28 evaluable patients, 13 (46%) were alive with no disease at
follow-up. Time to follow-up ranged from 18 months to 4 years.
Of the remaining patients, three (11%) were alive with disease
progression and 12 (43%) had died following disease relapse.
There was a greater likelihood of relapse for patients with higher
day 14 peak 4-oxo-13cisRA plasma concentrations (P¼0.014; Cox
regression analysis). No other pharmacokinetic parameters were
related to time to relapse or survival.
Treatment was reasonably well tolerated, although several
patients had persistent haematological toxicity following the
previous myeloablative therapy. Nine patients experienced some
form of mild skin toxicity (eight CTC grade 2, one grade 3), with
only one report of mild cheilitis. Hypercalcaemia (grade 2 or 3)
was reported in two patients. There was no evidence to suggest that
any of the toxicities observed were linked to the pharmacokinetics
of 13-cisRA or its metabolite.
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Figure 2 13-cis-retinoic acid data; course 2 for all patients shown by study day; separate graphs shown by method of administration. Patient 26 received
13cisRA via an NG tube.
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sDISCUSSION
The addition of 13-cisRA to the treatment of high-risk neuro-
blastoma has been shown to improve 3-year event-free survival
rates. Nevertheless, despite the addition of 13-cisRA to high-dose
myeloablative chemotherapy treatment protocols, more than half
of patients still suffer relapse within 3 years. While in some
patients relapse is mostly influenced by the biology of the tumour,
the high degree of variability in the pharmacokinetics and
metabolism of 13-cisRA observed in this study suggests that there
is scope for further improvements based on individualisation of
dosing or schedules.
A series of population pharmacokinetic models were fitted to
13-cisRA plasma concentration–time data from 28 children
with high-risk neuroblastoma. Following detailed analysis of these
data, the pharmacokinetics of 13-cisRA were best described by a
modified one-compartment, zero-order absorption model com-
bined with an absorption lag time. Some patients had almost no
absorption lag time followed by a very rapid absorption, whereas
in other patients a prolonged lag time was observed, together with
very slow absorption. Conversely, a very delayed but rapid rise in
plasma concentrations was seen in some patients. Thus, a relatively
complex model with an absorption lag time was required for all of
the standard models. However, the simple first- and zero-order
models did not fit particularly well when this approach was taken.
Use of the modified zero-order model or the transit model
provided a much better fit to the data.
The dosing regimen of 80mgm
 2 twice daily for 14 days was
associated with significant inter-patient variation in 13-cisRA
pharmacokinetics, comparable with that observed following ATRA
administration for the treatment of APL (Lanvers et al, 2003). For
13-cisRA, pharmacokinetics may be influenced by a number of
factors, including both the method of drug administration and the
extent of metabolism.
Children diagnosed with high-risk neuroblastoma are com-
monly aged between 1 and 5 years, presenting a practical problem
with regards to administering large numbers of 13-cisRA capsules.
For example, an average child of 5 years with a surface area of
0.75m
2 would require a daily dose of 120mg, administered as six
large 20mg capsules or 24 5mg capsules. Younger children are
therefore often unable to take 13-cisRA unless it is removed from
the capsules before administration. In addition to the safety
concerns that may arise from this practice, with regards to the
handling of a potentially teratogenic substance, opening the
capsule may impact on the actual dose of drug received. This
may reflect loss of drug during handling in addition to the well-
documented instability of 13-cisRA in the presence of light.
Of the 28 patients recruited to the current study, 17 (age 1.1–
10.7 years) required the capsules to be opened and the contents
mixed with food. Plasma concentrations of 13-cisRA in these
patients were significantly lower than those observed in children
who were able to swallow the capsules, although both groups
exhibited a wide variation in plasma concentrations. No attempt
was made to control food intake around the time of administra-
tion. A previous study has reported higher plasma concentrations
when 13-cisRA was administered within 1h before or after a
standard meal, compared with the fasted state (Colburn et al,
1983). Application of the data presented here to guide dosing of
13-cisRA would also need to be adapted to reflect differences in
the administration of 13-cisRA in different countries, for example
punching a hole in the capsule so that it can be chewed before
swallowing. The younger children, for whom the capsules were
most likely to have been opened, also received the lowest absolute
doses in milligrams.
Following oral administration, 13-cisRA may be subject to first-
pass metabolism and subsequent plasma concentrations will
depend on the rate and extent of metabolism to 4-oxo-13-cisRA,
generally thought to represent a pathway of retinoid inactivation.
Oxidative metabolism has previously been observed in studies with
ATRA (Muindi et al, 1992; Rigas et al, 1993) and fenretinide
(Villani et al, 2004), and auto-induction of oxidative metabolism
has been associated with disease relapse, following chronic
administration of ATRA in APL (Muindi et al, 1992). This can
be avoided by the use of intermittent ATRA dosing schedules
(Adamson et al, 1995), an approach that has also been
recommended to minimise the side effects of ATRA in children
(Lanvers et al, 2003). Our results with 13-cisRA show an
accumulation of the 4-oxo-metabolite between days 1 and 14 of
treatment in all patients, with metabolite concentrations higher
than those of the parent drug by day 14 in approximately 70% of
patients. There was no corresponding decrease in parent drug
concentrations, which would have indicated enzyme induction.
Thus, repeated dosing of 13cisRA is unlikely to be associated with
cytochrome P450 (CYP) enzyme induction, as is seen with ATRA
(Adamson et al, 1993).
With the limited size of the current study, it is difficult to obtain
a clear indication of the impact of inter-patient pharmacokinetic
variation and metabolism of 13-cisRA on clinical efficacy or
toxicity. The degree of toxicity was similar to that reported in the
Phase I study of 13-cisRA at the equivalent dose level (Villablanca
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Figure 3 Area under the curve of 13-cisRA observed on day 1 of course
2 of treatment in patients who swallowed 13-cisRA capsules vs those
patients for whom the capsules were opened and the contents mixed with
food before administration. Median values are identified with a cross.
Table 4 Summary statistics for 13-cisRA Cmax and 4-oxo-13-cisRA
Cmax on study day 1 and 14, analysed by course
Parameter Course N Mean s.d.
13-cisRA
Day 1 (mM) 2 27 2.78 2.31
4 13 5.43 2.23
6 10 3.25 1.99
Day 14 (mM) 2 27 2.83 1.44
4 13 4.71 2.40
6 10 2.52 1.85
4-oxo-13-cisRA
Day 1 (mM) 2 27 1.30 1.21
4 13 1.84 0.85
6 10 1.31 0.74
Day 14 (mM) 2 27 4.67 3.17
4 13 6.43 4.11
6 10 3.49 1.98
Abbrevitions: RA¼retinoic acid; s.d.¼standard deviation.
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set al, 1995). A statistically significant relationship was observed
between the incidence of disease relapse and plasma metabolite
concentrations, with an increased likelihood of relapse for patients
with higher day 14 peak 4-oxo-13-cisRA levels. A corresponding
decrease in parent drug was not detectable. It should be noted that
older patients, who may have a higher risk of relapse, would
receive higher doses of unopened capsules.
As lower doses of retinoic acid have been shown to be ineffective
in the treatment of neuroblastoma (Matthay et al, 1999; Kohler
et al, 2000), the extent of inter-patient pharmacokinetic variation
following high-dose 13-cisRA therapy warrants further investiga-
tion. Individuals with plasma concentrations below those asso-
ciated with antitumour activity may require an increased dose.
One approach to overcome interindividual variation, and to ensure
that plasma concentrations are not compromised by the method of
administration, would be to monitor plasma concentrations on day
1 of treatment. Data in Figure 2 indicate that plasma concentra-
tions do not vary substantially between days of treatment, thus
dose adjustment based on the day 1 plasma concentrations is
feasible.
It is notable that the plasma concentrations achieved in the
current study are up to four-fold lower than those reported in a
phase I study of the same formulation (Khan et al, 1996). The
reasons for this difference are not easily identified. The age range,
and thus the doses administered, in the phase I study population
are not different to that studied here. It may be that the method of
administration was different in the previous study, although the
difference in AUC is equally marked in our patients who swallowed
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6 10 16 17
18 19 20 22
24 25 27 29
3 7 8 11
12 14 15 21
23 26 28
Opened and mixed with food 
10
5
0
10
5
0
10
5
0
10
5
0
10
5
0
10
5
0
10
5
0
400 200 0 400 200 0
400 200 0 400 200 0
400 200 0
400 200 0 400 200 0
400 200 0
Swallowed 
Time (min)
Time (min)
4
-
o
x
o
-
1
3
-
c
i
s
R
A
 
(

M
)
4
-
o
x
o
-
1
3
-
c
i
s
R
A
 
(

M
)
Day
1
14
Day
1
14
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sthe capsules whole. There are differences in the assay for drug and
metabolite in plasma, but our method was stringently validated
and rigorous efforts were employed to minimise loss of drug due to
photodegradation. Data on ATRA and the 4-oxo metabolite are
comparable between the two studies, although little detail is given
in the phase I report (Khan et al, 1996).
The conversion to 4-oxo-13-cisRA is the major route of 13-cisRA
metabolism. Although there was no indication that this led to
significantly lower parent retinoid levels during treatment, higher
13-cisRA levels may be achieved by limiting the extent of
metabolism. Although oxidation of 13-cisRA may be mediated by
a number of enzymes (Sonneveld et al, 1998; Nadin and Murray,
1999; Chen et al, 2000), specific inhibitors of retinoid metabolism,
such as R116010, may be used to inhibit such oxidation
(Armstrong et al, 2005) and thus may increase 13-cisRA plasma
concentrations. These data also indicate that lower systemic 13-
cisRA exposures are associated with the practice of opening the
capsules and mixing the contents with food before administration.
This finding highlights the importance of obtaining appropriate
pharmaceutical formulations of medicines for children. Although a
simple increase in 13-cisRA dose is likely to overcome this
problem, it may be more appropriate to design a study
incorporating the monitoring of plasma concentrations, with a
view to standardisation of drug exposure and the development of
more robust pharmacokinetic–pharmacodynamic relationships.
The data presented here show that optimisation of dosing of 13-
cisRA in high-risk neuroblastoma is possible, based on knowledge
of the clinical pharmacology of this drug.
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